This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Derek M. Meisner net worth and biography

Derek Meisner Biography and Net Worth

General Counsel of X4 Pharmaceuticals

Derek Meisner, J.D., serves as Chief Legal Officer and Corporate Secretary at X4. Mr. Meisner brings more than two decades of experience providing counsel to public and private companies across key legal and operational functions, including regulatory compliance, debt and equity financings, mergers and acquisitions, strategic partnerships and corporate governance. Most recently, Mr. Meisner held the role of General Counsel at Genocea Biosciences, a Cambridge-based, publicly traded, clinical-stage biopharmaceutical company. Prior to Genocea, he served as General Counsel of multiple Boston-based financial services firms, including prominent life science investor RA Capital Management, and he was previously a partner at the international law firm K&L Gates and Branch Chief in the Division of Enforcement of the U.S. Securities and Exchange Commission. Mr. Meisner holds a B.A. from the University of Michigan and a J.D. from the Washington College of Law at American University.

What is Derek M. Meisner's net worth?: The estimated net worth of Derek M. Meisner is at least $140,438.43 as of January 19th, 2024. Mr. Meisner owns 108,867 shares of X4 Pharmaceuticals stock worth more than $140,438 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Meisner may own. Learn More about Derek M. Meisner's net worth.
How do I contact Derek M. Meisner?: The corporate mailing address for Mr. Meisner and other X4 Pharmaceuticals executives is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. X4 Pharmaceuticals can also be reached via phone at (857) 529-8300 and via email at [email protected]. Learn More on Derek M. Meisner's contact information.
Has Derek M. Meisner been buying or selling shares of X4 Pharmaceuticals?: Derek M. Meisner has not been actively trading shares of X4 Pharmaceuticals in the last ninety days. Learn More on Derek M. Meisner's trading history.
Who are X4 Pharmaceuticals' active insiders?: X4 Pharmaceuticals' insider roster includes Derek Meisner (General Counsel), Adam Mostafa (CFO), and Paula Ragan (CEO). Learn More on X4 Pharmaceuticals' active insiders.
Are insiders buying or selling shares of X4 Pharmaceuticals?: During the last twelve months, X4 Pharmaceuticals insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $30,000.00. During the last twelve months, insiders at the sold shares 24 times. They sold a total of 901,833 shares worth more than $790,527.04. The most recent insider tranaction occured on March, 11th when insider Arthur Taveras sold 14,235 shares worth more than $12,526.80. Insiders at X4 Pharmaceuticals own 1.1% of the company. Learn More about insider trades at X4 Pharmaceuticals.
Information on this page was last updated on 3/11/2024.

Derek M. Meisner Insider Trading History at X4 Pharmaceuticals

Derek M. Meisner Buying and Selling Activity at X4 Pharmaceuticals

X4 Pharmaceuticals Company Overview

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Today's Range

Now: $1.29

$1.22

$1.29

50 Day Range

MA: $1.13

$0.84

$1.47

2 Week Range

Now: $1.29

$0.57

$2.58

Volume

2,231,367 shs

Average Volume

2,707,890 shs

Market Capitalization

$216.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49